Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin A - AbbVie/Medytox

X
Drug Profile

Botulinum toxin A - AbbVie/Medytox

Alternative Names: ABBV-950; Botulift; Botulinum toxin type A; Cunox; Innotox; KbtxA; Liquid-type botulinum toxin type A - AbbVie; MBA-P01; Meditoxin; MT 10107; MT 10109; MT10109L; Neuronox; NivobotulinumtoxinA; Siax

Latest Information Update: 01 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medy-Tox
  • Developer AbbVie; Medytox
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Blepharospasm; Equinus foot deformity; Glabellar lines; Muscle spasticity; Spasm
  • Phase III Facial wrinkles; Hyperhidrosis; Overactive bladder; Torticollis
  • No development reported Hypertrophy

Most Recent Events

  • 12 Jan 2024 Phase-I/II clinical trials in Muscle spasticity in USA (IM) (NCT05956509)
  • 05 Jan 2024 Medytox announces intention to seek approval for NivobotulinumtoxinA in the US and Canada
  • 31 Dec 2023 Medytox submitted BLA to the US FDA for Botulinum toxin
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top